ArticleLaryngoscope investigative otolaryngology2022
Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma.
Article in Laryngoscope investigative otolaryngology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Precision Diagnosis in Cutaneous Head and Neck Squamous Cell Carcinoma.Biomedicines · 2026Review
- Special Issue on Skin Cancers of the Head and Neck.Cancers · 2025Article
- The Role of Gene Expression Profiling in the Management of Cutaneous Squamous Cell Cancer: A Review.Cancers · 2024Review
- Metastatic patterns and treatment options for head and neck cutaneous squamous cell carcinoma (Review).Molecular and clinical oncology · 2024Review
- Review
- Dermatologic Disease-Directed Targeted Therapy (DDermatology and therapy · 2022Review
- Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma.Laryngoscope investigative otolaryngology · 2022Article
- Predicting Behavior of Cutaneous Head and Neck Squamous Cell Carcinoma in Transplant Recipients.OTO openArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOver 50% of newly diagnosed cutaneous squamous cell carcinoma (cSCC) lesions occur in the head and neck (cSCC-HN), and metastasis to nodal basins in this region further complicates surgical and adjuvant treatment. The current study addressed whether the 40-gene expression profile (40-GEP) test can predict metastatic risk in cSCC-HN with improved accuracy and provide independent prognostic value to complement current risk assessment methods. STUDY
designMulticenter, retrospective cohort study.
methodsFormalin-fixed paraffin-embedded primary tumor tissue and associated clinical data from patients with cSCC-HN (
resultsThe 40-GEP test classified the cohort into low (Class 1,
conclusionsImproved metastatic risk stratification through the 40-GEP test could complement cSCC-HN risk assessment for better-informed decision-making for treatment and surveillance and ultimately improve patient outcomes. LEVEL OF EVIDENCE: 3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.